Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation
Authors:
- 14 August 2015
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 10 (4) , 1460-1466
Abstract
The aim of the present study was to investigate the therapeutic efficacy of immunotherapy after microwave ablation (MWA), which was used to improve liver function, reduce the recurrence rate and enhance survival period in patients with hepatocellular carcinoma (HCC). Between February 2009 and December 2010, 14 patients received immunotherapy after MWA (immunotherapy group) and 15 patients received MWA alone with no post-ablated adjuvant therapy (control group). Immune and liver parameters, recurrence rate and survival time were recorded. The absolute lymphocyte count in the immunotherapy group exceeded that in the control group after 3 courses of immunotherapy (P0.05); however, certain cytotoxic subsets (CD3(+)/CD8(+), CD8(+)CD28(+) and CD3(+)CD16(+)CD56(+) T cells) were over-represented and negative regulatory or helper subsets (CD4(+)CD8(+), CD4(+), CD4(+)CD25(+)) were under-represented in the immunotherapy group between 1 and 12 months after immunotherapy (P0.05). In conclusion, the results of the present study indicate that immunotherapy improves the immune status and liver function of patients with HCC.Keywords
This publication has 22 references indexed in Scilit:
- Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic reviewInternational Journal Of Clinical Practice, 2011
- Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinomaCancer Biology & Therapy, 2011
- Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation.Cancer Biology & Therapy, 2010
- Predictors of microvascular invasion before hepatectomy for hepatocellular carcinomaJournal of Surgical Oncology, 2010
- A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinomaDigestive and Liver Disease, 2009
- Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004†Hepatology, 2008
- Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular CarcinomasJournal of Immunotherapy, 2008
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trialThe Lancet, 2000
- Hematogenous Spreading of Hepatocellular Carcinoma Cells: Possible Participation in Recurrence in the LiverHepatology, 1997